Hammersmith Medicines Research
Generated by Meeveem AI
"Leading European CRO specialising in early phase clinical trials for pharmaceutical innovators"
London
•251 - 500 Employees
•Contract Research
About Hammersmith Medicines Research
Hammersmith Medicines Research conducts phase 1 and early phase 2 clinical trials for pharmaceutical and biotechnology companies worldwide. Since 1993, the company has completed over 900 trials in a purpose-built 145 bed facility in London, providing fully integrated services from study design to final clinical report. The team of 270 specialists includes 10 physicians, 40 nurses, and over 120 graduates or PhDs. HMR serves the top 15 pharmaceutical companies and more than 200 SMEs across 23 countries. The facility holds MHRA phase 1 accreditation, multiple ISO certifications, and a manufacturing licence for investigational medicinal products. This enables complex trials including first in human studies, radiopharmacy and biologics.
270
Team Members
1993
Founded
Contract Research
Sector
On-Site
Work Environment
Our Vision
A world where medicines reach patients faster through rigorous, efficient early phase clinical research that sets the standard for safety and scientific excellence.
Our Mission
Hammersmith Medicines Research exists to achieve the highest ethical, medical and scientific standards in the study of potential new medicines in humans, with the ultimate aim of improving the prevention and treatment of disease.